Obesity in Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2031
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Obesity Market Report Overview
The total obesity market was $2.43 billion across the 7MM in 2021 and will achieve a CAGR of more than 31% during 2021-2031. The diabetic population is set to grow in line with the increased prevalence of risk factors such as obesity, which will drive market growth during the forecast period.
Obesity Market Outlook, 2021-2031 ($ Billion)
Buy the Full Report to Gain More Information on the Obesity Market Forecast
The obesity market research covers the 7MM (the US, France, Germany, Italy, Spain, and the UK) and provides a forecast model for the obesity market through 2031.
Market Size (2021) | $2.43 billion |
CAGR (2021-2031) | >31% |
Key Class of Drugs | · Saxenda (liraglutide)
· Victoza (liraglutide) (OFF-LABEL) · Liraglutide biosimilar · Wegovy (semaglutide) · Ozempic (semaglutide) (OFF-LABEL) |
Leading Players | · Novo Nordisk
· Eli Lilly · Pfizer · Boehringer Ingelheim · Zealand Pharma |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Obesity Market Insights
Expensive therapies will face reimbursement challenges in markets where cost-conscious decisions are increasingly implemented, which will negatively impact the market growth during the forecast period. However, therapies with new routes of will administration enter the market such as Novo Nordisk’s oral semaglutide (NN-9932), Eli Lilly’s orforglipron, and Pfizer’s PF-07081532 and danuglipron tromethamine will propel the market growth in the near future.
Obesity - Treatment Insights
- There will be increased demand for a wider range of pharmacotherapy treatments for patients as the obesity epidemic continues to spread. Current drug treatment options for obesity are dominated by GLP-1R agonist therapies, which include semaglutide and liraglutide along with the off-label use of tirzepatide and oral semaglutide in some of the 7MM.
- Physicians most often recommend dietary changes and increased physical activity to treat obesity. However, clinical practice favors conservative treatment options relying on behavioral modification for patients with Class I and Class II obesity.
- In some cases, interventional treatment options are offered to patients with obesity. For instance, Roux-en-Y gastric bypass, biliopancreatic diversion with duodenal switch (BDP/DS), and sleeve gastrectomy collectively comprise the various types of bariatric surgery, a procedure in which stomach size is reduced to limit the amount of food eaten by the individual and decrease nutrient absorption.
Buy the Full Report for More Obesity Treatment Insights
Obesity Market Segmentation by Class of Drugs
In 2021, the leading global drug class obesity market was Ozempic (semaglutide) (OFF-LABEL).
The key classes of drugs in the US obesity market are Saxenda (liraglutide), Victoza (liraglutide) (OFF-LABEL), Liraglutide biosimilar, Wegovy (semaglutide), and Ozempic (semaglutide) (OFF-LABEL). The Ozempic establishes market-leading GLP-1RA therapy because many patients having T2D are obese and already have coverage for this treatment. Furthermore, the off-label use by the celebrity hype around Ozempic’s weight loss potential.
Obesity Market Analysis by Class of Drugs, 2021 (%)
Buy the Full Report for More Drugs Insights into the Obesity Market
Obesity Market - Competitive Landscape
A few of the leading players in the obesity market are:
- Novo Nordisk
- Eli Lilly
- Pfizer
- Boehringer Ingelheim
- Zealand Pharma
Novo Nordisk’s Wegovy (semaglutide) and Eli Lilly’s tirzepatide are set to relaunch and launch, respectively at the beginning of the forecast period, whereas Novo Nordisk’s CagriSema and Eli Lilly’s retatrutide are currently in the late-stage pipeline. Moreover, the penetration of these therapies within the obesity market can revolutionize the obesity space due to their improved efficacies and once-weekly administration rates.
Obesity Market Analysis by Companies
Buy the Full Report for More Obesity Company Insights
Scope
- Understand the epidemiology, symptoms, diagnosis, and management of obesity, to get a better overview of the market.
- Annualized obesity market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2021 to 2031.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the obesity therapeutics market.
- Comprehensive data assessing emerging trends and mechanisms of action under development for obesity treatment. The most promising candidates in Phase III and Phase IIb development are profiled.
- Analysis of the current and future market competition in the global obesity therapeutics market.
- Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
Key Highlights
Report deliverables include a Word report and an Excel-based forecast model
Forecast includes the 7 major markets (7MM)
Forecast covers the period 2021-2031
• Drug sales in the obesity pharmacotherapy market are expected to grow by a significant margin between 2021 and 2031, with an overall compound annual growth rate (CAGR) of 31.3% over the forecast period, reaching $37.1 billion by 2031.
• Growth in the obesity market will be driven by the launch of 13 new pipeline products, including Novo Nordisk’s Wegovy (semaglutide), CagriSema (semaglutide + cagrilintide), and oral semaglutide (NN-9932), Eli Lilly’s tirzepatide, retatrutide, and orforglipron, Versanis Bio’s bimagrumab (BYM338), and Pfizer’s PF-07081532 and danuglipron tromethamine.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM Obesity therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM Obesity therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Eli Lilly
Pfizer
Boehringer Ingelheim
Zealand Pharma
OPKO Health
Versanis Bio Inc.
Rhythm Pharmaceuticals
Roche
H2-Pharma
Chelapharm
Vivus Inc.
Orexigen Therapeutics
Currax Pharmaceuticals
FUJIFILM Toyama Chemical Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What was the obesity market size across the 7MM in 2021?
The obesity market size across the 7MM was $2.43 billion in 2021.
-
What will the obesity market growth rate be during the forecast period?
The obesity market will achieve a CAGR of more than 31% during 2021-2031.
-
Which drug was the highest selling in the obesity market in 2021?
Ozempic (semaglutide) (OFF-LABEL) was the highest-selling drug in 2021.
-
Who are the leading players in the obesity market?
A few of the leading players in the obesity market are Novo Nordisk, Eli Lilly, Pfizer, Boehringer Ingelheim, Zealand Pharma among others.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.